Search | Clinical Trials Finder

Conditions: Hypersensitivity, Immediate
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 19 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Asthma
Interventions: JNJ-43260295, Placebo, Nasal Allergen Challenge; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Asthma, Obesity, Inflammation
Interventions: Montelukast, Placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 7 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Allergic Asthma
Interventions: Whole lung antigen challenge, segmental allergen challenge; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Moderate to Severe Allergic Asthma
Interventions: CYT003, Placebo; Biological
Lead sponsor: Cytos Biotechnology AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more

Conditions: Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 80 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma, Atopy
Interventions: Standardized Cat Allergen Extract and Standardized Dust Mite Allergen, Computed Tomography imaging, functional Positron Emission Tomography imaging, Nebulized methacholine inhalation; Biological · Radiation · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma, Allergic
Interventions: Ozone, FA; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: QAW039, Placebo QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 30
States / cities: Encinitas, California • Huntington Beach, California • Los Angeles, California + 24 more

Conditions: Asthma, Allergic
Interventions: Bronchoscopy/BAL, Airway Brushing; Procedure
Lead sponsor: Andrew D. Luster, M.D.,Ph.D.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allergic Asthma
Interventions: Placebo, Omalizumab, Immunotherapy; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Airway Inflammation, Allergic Asthma
Interventions: Wood Smoke Particles (WSP); Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Allergic Asthma, Allergic Rhinitis
Interventions: Not listed
Lead sponsor: Creighton University; Other
Eligibility: 12 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Allergic Asthma
Interventions: omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more

Conditions: Lung Disease
Interventions: Placebo, Xolair; Drug
Lead sponsor: Creighton University; Other
Eligibility: 12 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Omaha, Nebraska • Albany, New York

Conditions: Asthma
Interventions: QAW039, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 55
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more

Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions: Specimen sample; Diagnostic Test
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Allergic Asthma
Interventions: Omalizumab, Placebo, Asthma therapies; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 17 Years to 70 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 100
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more

Conditions: Asthma
Interventions: Aerovant, placebo; Drug · Other
Lead sponsor: Aerovance, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Mobile, Alabama • Scottsdale, Arizona • Huntington Beach, California + 31 more

Conditions: Allergic Asthma
Interventions: gamma tocopherol, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: QGE031; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Evansville, Indiana • Owensboro, Kentucky • Waldorf, Maryland + 2 more

Conditions: Asthma, Allergies
Interventions: Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage, Phlebotomy; Biological · Procedure
Lead sponsor: Andrew D. Luster, M.D.,Ph.D.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allergic Asthma
Interventions: Albuterol sulfate; Drug
Lead sponsor: Respirics Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Asthma
Interventions: QAW039, Montelukast, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 38
States / cities: Scottsdale, Arizona • Encinitas, California • Huntington Beach, California + 33 more

Search by objective public record fields.

Clinical and Immunological Evaluation of Children With Allergies

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics

AsthMatic Inflammation and Neurocircuitry Activation (MINA)

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

Imaging Study of the Lungs During an Allergic Asthma Attack

Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ)

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

Lung-Resident Memory Th2 Cells in Asthma

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility

Effect of Montelukast on Basophils, In-vitro

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL

Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma

Study Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI

Dose Finding Study for QAW039 in Asthma